Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed? [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
imatinib-treated Gastrointestinal Stromal Tumor patients under the Real-Time Oncology Review program, following Phase 3 data showing improved progression-free survival and response rates versus sunitinib alone. This marks a potential first-in-class combination option for a population with limited treatment choices, highlighting how RTOR can accelerate access to promising oncology therapies. We'll now examine how the RTOR-based review of bezuclastinib's GIST data shapes Cogent Biosciences' investment narrative and future prospects. These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Cogent Biosciences today, you have to believe bezuclastinib can transition from a promising clinical asset into a real commercial franchise across GIST and systemic mastocytosis, while the broader pipeline slowly adds depth. The FDA's Real-Time Oncology Review for the bezuc
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent Biosciences (NASDAQ:COGT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $55.00 price target on the stock.MarketBeat
- Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) GlobeNewswire
- Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies PortfolioGlobeNewswire
- Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge [Yahoo! Finance]Yahoo! Finance
- H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) [Yahoo! Finance]Yahoo! Finance
COGT
Sec Filings
- 1/21/26 - Form SCHEDULE
- 1/21/26 - Form SCHEDULE
- 1/5/26 - Form 4
- COGT's page on the SEC website